Product Information:

TIRZEE 10mg Pen contains Tirzepatide 10mg, a once-weekly dual GIP and GLP-1 receptor agonist used for the treatment of type 2 diabetes mellitus and chronic weight management in adults. Tirzepatide simultaneously activates glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, resulting in enhanced insulin secretion, suppressed glucagon release, slowed gastric emptying, and increased satiety.

The 10mg dose is a high-efficacy maintenance dose, typically used after successful titration through lower doses (2.5mg → 5mg → 7.5mg), and is associated with robust metabolic improvements.

✅ Note: This aligns with globally approved regimens (e.g., Mounjaro® for diabetes; Zepbound® for obesity), where 10mg is a standard therapeutic dose for significant glycemic and weight control.

Uses of (TIRZEE 10MG PEN):

1. Type 2 diabetes mellitus – for patients requiring intensive glycemic control
2. Chronic weight management – for sustained appetite suppression and meaningful fat loss
3. May improve cardiovascular risk factors (blood pressure, lipids, liver fat)

Key Benefits of (TIRZEE 10MG PEN):

1. Once-weekly subcutaneous injection – convenient and adherence-friendly
2. Dual incretin action provides superior HbA1c reduction (up to 2.3–2.5%)
3. Promotes substantial weight loss (average 15–20% of body weight in clinical trials at higher doses; ~12–15% at 10mg)
4. Improves insulin sensitivity and beta-cell function
5. Low risk of hypoglycemia when not combined with insulin or sulfonylureas

How To Use (TIRZEE 10MG PEN):

1. Inject once weekly, on the same day each week, with or without meals.
2. Administer subcutaneously in the abdomen, thigh, or upper arm.
3. Do not inject intravenously or intramuscularly.
4. Dose escalation protocol:
5. Weeks 1–4: 2.5mg once weekly
6. Weeks 5–8: 5mg once weekly
7. Weeks 9–12: 7.5mg once weekly
8. Week 13 onward: 10mg once weekly
9. May escalate further to 12.5mg or 15mg if needed and tolerated
10. If a dose is missed, administer within 4 days; if >4 days, skip and resume on the next scheduled day.

When Not to Use (TIRZEE 10MG PEN):

Do not use if you have:

1. Personal or family history of medullary thyroid carcinoma (MTC)
2. Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
3. Hypersensitivity to tirzepatide or any excipients
4. Type 1 diabetes or diabetic ketoacidosis

⚠️ Black Box Warning:

Tirzepatide causes thyroid C-cell tumors in rodents. It is contraindicated in patients with MTC risk.

Side Effects of (TIRZEE 10MG PEN):

Common (more frequent at this dose, but usually transient):

1. Nausea, vomiting, diarrhea, constipation
2. Decreased appetite, abdominal pain or discomfort
3. Fatigue, dizziness
4. Injection site reactions (redness, itching)

Less common:

1. Elevated amylase/lipase levels
2. Gallbladder-related events (biliary colic, cholecystitis)

Serious (rare but require monitoring):

1. Acute pancreatitis (persistent severe upper abdominal pain radiating to back)—discontinue immediately
2. Gallbladder disease (may require surgical intervention)
3. Acute kidney injury (from dehydration due to GI losses)
4. Worsening diabetic retinopathy (in patients with pre-existing proliferative disease)
5. Seek emergency care if severe abdominal pain, vision changes, or persistent vomiting occurs.

Dosage: (TIRZEE 10MG PEN):

1. High-efficacy maintenance dose: 10mg once weekly
2. Only initiate after completing ≥4 weeks on 7.5mg
3. Maximum dose: 15mg once weekly

Who It’s For (TIRZEE 10MG PEN):

Adults with type 2 diabetes or obesity who have tolerated lower doses and require maximal glycemic control or significant weight reduction, and who can manage potential gastrointestinal side effects.

Warnings & Precautions:

1. Maintain adequate daily fluid intake to prevent dehydration and renal injury
2. Monitor renal function and gallbladder health periodically
3. Use caution in patients with history of pancreatitis, gallstones, eating disorders, or proliferative diabetic retinopathy
4. Educate on recognizing signs of serious adverse events

Drug Interactions:

1. Insulin or sulfonylureas: ↑ Risk of hypoglycemia—monitor blood glucose closely
2. Oral medications: May delay absorption—administer ≥1 hour before or 4+ hours after tirzepatide
3. Always inform your doctor about all medications and supplements.

Additional Information:

1. Store unused pens refrigerated (2–8°C); after first use, store at room temperature (<30°C) for up to 28 days.
2. Do not freeze. Protect from light.
3. Keep out of reach of children. Available by prescription in Pakistan.